Bristol-Myers Squibb Stock News

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult.

Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio.

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new oncology registrational trials added in past year, as the management seeks to deliver new growth opportunities in the face of upcoming patent cliff. These developments also lend strength to BMY's Growt...

Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has promising new drugs like Cobenfy to offset potential revenue declines. Recent quarterly results show solid revenue growth, though earnings per share have declined, and management has raised revenue ...

If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio.

MIDDLETON, Wis.--(BUSINESS WIRE)-- #HealthtechInnovation--Imbed Biosciences today announced that Terry Bromley has joined as Chief Executive Officer. With over 30 years of experience in the medical device, regenerative medicine and wound and skin markets, Mr. Bromley will be instrumental in fostering the company's growth and continue Imbed Biosciences' mission to transform the future of soft ti...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025.